References
- Boersma BJ, Howe TM, Goodman JE, et al (2006). Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst, 98, 911-9. https://doi.org/10.1093/jnci/djj245
- Bond GL, Hu W, Bond EE, et al (2004). A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell, 119, 591-602. https://doi.org/10.1016/j.cell.2004.11.022
- Bond GL, Hu W, Levine A (2005). A single nucleotide polymorphism in the MDM2 gene: from a molecular and cellular explanation to clinical effect. Cancer Res, 65, 5481-4. https://doi.org/10.1158/0008-5472.CAN-05-0825
- Bouska A & Eischen CM (2009). Mdm2 affects genome stability independent of p53. Cancer Res, 69, 1697-701. https://doi.org/10.1158/0008-5472.CAN-08-3732
- Detchokul S & Frauman AG (2011). Recent developments in prostate cancer biomarker research: therapeutic implications. Br J Clin Pharmacol, 71, 157-74. https://doi.org/10.1111/j.1365-2125.2010.03766.x
- Eischen CM & Lozano G (2009). p53 and MDM2: antagonists or partners in crime? Cancer Cell, 15, 161-2. https://doi.org/10.1016/j.ccr.2009.02.004
- Jaboin JJ, Hwang M, Perez CA, et al (2011). No evidence for association of the MDM2-309 T/G promoter polymorphism with prostate cancer outcomes. Urol Oncol, 29, 319-23. https://doi.org/10.1016/j.urolonc.2009.03.031
- Kibel AS, Jin CH, Klim A, et al (2008). Association between polymorphisms in cell cycle genes and advanced prostate carcinoma. Prostate, 68, 1179-86. https://doi.org/10.1002/pros.20784
- Kruse JP & Gu W (2009) . Modes of p53 regulation. Cell, 137, 609-22. https://doi.org/10.1016/j.cell.2009.04.050
- Liu J, Zheng Y, Lei D, et al (2011). MDM2 309T>G polymorphism and risk of squamous cell carcinomas of head and neck: a meta-analysis. Asian Pac J Cancer Prev, 12, 1899-903.
- Ma H, Hu Z, Zhai X, et al (2006). Polymorphisms in the MDM2 promoter and risk of breast cancer: a case-control analysis in a Chinese population. Cancer Lett, 240, 261-7. https://doi.org/10.1016/j.canlet.2005.09.019
- Ma HB, Huang T, Han F, et al (2012). Association Between MDM2 Promoter SNP309 T/G Polymorphism and Liver Cancer Risk - a Meta-analysis. Asian Pac J Cancer Prev, 13, 2841-6. https://doi.org/10.7314/APJCP.2012.13.6.2841
- Mandal RK, Mittal RD (2010). Are cell cycle and apoptosis genes associated with prostate cancer risk in North Indian population? Urol Oncol, 30, 555-61.
- Nunobiki O, Ueda M, Yamamoto M, et al (2010). MDM2 SNP 309 human papillomavirus infection in cervical carcinogenesis. Gynecol Oncol, 118, 258-61. https://doi.org/10.1016/j.ygyno.2010.05.009
- Ohmiya N, Taguchi A, Mabuchi N, et al (2006). MDM2 promoter polymorphism is associated with both an increased susceptibility to gastric carcinoma and poor prognosis. J Clin Oncol, 24, 4434-40. https://doi.org/10.1200/JCO.2005.04.1459
- Stoehr R, Hitzenbichler F, Kneitz B, et al (2008). Mdm2- SNP309 polymorphism in prostate cancer: no evidence for association with increased risk or histopathological tumour characteristics. Br J Cancer, 99, 78-82. https://doi.org/10.1038/sj.bjc.6604441
- Sun T, Lee GS, Oh WK, et al (2010). Single-nucleotide polymorphisms in p53 pathway and aggressiveness of prostate cancer in a Caucasian population. Clin Cancer Res, 16, 5244-51. https://doi.org/10.1158/1078-0432.CCR-10-1261
- Vassilev LT, Vu BT, Graves B, et al (2004). In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science, 303, 844-8. https://doi.org/10.1126/science.1092472
- Xu B, Xu Z, Cheng G, et al (2010). Association between polymorphisms of TP53 and MDM2 and prostate cancer risk in southern Chinese. Cancer Genet Cytogenet, 202, 76-81. https://doi.org/10.1016/j.cancergencyto.2010.02.014
- Yoon YJ, Chang HY, Ahn SH, et al (2008). MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis, 29, 1192-6. https://doi.org/10.1093/carcin/bgn090
Cited by
- Association Between MDM2 SNP309 T>G and Risk of Gastric Cancer: A Meta-analysis vol.14, pp.3, 2013, https://doi.org/10.7314/APJCP.2013.14.3.1925
- MDM2 SNP309 variation increases cervical cancer risk among Asians vol.35, pp.6, 2014, https://doi.org/10.1007/s13277-014-1695-5
- Genetic association of single nucleotide polymorphisms in P53 pathway with gastric cancer risk in a Chinese Han population vol.32, pp.1, 2015, https://doi.org/10.1007/s12032-014-0401-1
- Murine Double Minute 2 Gene Polymorphism Is an Independent Prognostic Factor for Patients with Renal Cell Carcinoma vol.34, pp.2, 2015, https://doi.org/10.1089/dna.2014.2653
- Impact of MDM2 Single Nucleotide Polymorphism on Oral Squamous Cell Carcinoma Risk vol.71, pp.2, 2015, https://doi.org/10.1007/s12013-014-0298-5
- Association of MDM2 promoter T309G polymorphism with oral cancer risk: A meta-analysis of 3,536 subjects vol.5, pp.1, 2016, https://doi.org/10.3892/mco.2016.868